{"id":130220,"date":"2025-03-13T07:46:03","date_gmt":"2025-03-13T07:46:03","guid":{"rendered":"https:\/\/peraltafinancing.com\/business\/legal\/has-glp-1-compounding-come-to-an-end\/"},"modified":"2025-03-13T07:46:03","modified_gmt":"2025-03-13T07:46:03","slug":"has-glp-1-compounding-come-to-an-end","status":"publish","type":"post","link":"https:\/\/fivemor.com\/?p=130220","title":{"rendered":"Has GLP-1 Compounding Come to an End?"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div>\n<p>Compounding GLP-1 medications, drugs related to immensely popular name-brand drugs such as Ozempic and Wegovy, has been going on since 2022 despite issued <a href=\"https:\/\/sandbergphoenix.com\/service\/patents\/\">patents<\/a> covering these name-brand drugs.\u00a0 This is because the <a href=\"https:\/\/www.fda.gov\/\">FDA<\/a> suspended enforcement of patents covering these name-brand drugs due to the inability of the drug owner and patent holder, Novo Nordisk, to meet the overwhelming demand for the drug.\u00a0 This enforcement suspension allowed state-licensed compounding pharmacies and outsourcing facilities, which make compounded drugs in bulk, to begin making their versions of these drugs.\u00a0 Compounding refers to the process of mixing, altering, or combining ingredients to create a medication, usually in tiny batches. \u00a0Following this decision by the FDA, the industry exploded overnight with thousands of these facilities producing GLP-1 drugs.<\/p>\n<p>On March 10, the FDA declared that the shortage was over and ordered the compounding pharmacies and outsourcing facilities to stop making them by April 22 and May 22, respectively.\u00a0 However, enforcement may be further delayed due to a requested injunction in a court case filed by the Outsourcing Facility Association against the FDA.\u00a0 If you\u2019ve received a cease and desist letter, you\u2019re not alone, as Novo Nordisk has wasted no time sending cease and desist letters to potential infringers.<\/p>\n<p>Whether or not Novo Nordisk will ultimately be successful remains to be seen, as there will likely be multiple challenges to these patents and all of the ensuing enforcement actions.<\/p>\n<p>Have you received a cease and desist letter from Novo Nordisk, or any other entity?\u00a0 Rest assured, the <a href=\"https:\/\/sandbergphoenix.com\/people\/?practice-group=intellectual-property\">attorneys<\/a> at Sandberg Phoenix are ready to help you understand your options and respond appropriately.<\/p>\n<\/p><\/div>\n\n","protected":false},"excerpt":{"rendered":"<p>Compounding GLP-1 medications, drugs related to immensely popular name-brand drugs such as Ozempic and Wegovy, has been going on since 2022 despite issued patents covering these name-brand drugs.\u00a0 This is because the FDA suspended enforcement of patents covering these name-brand drugs due to the inability of the drug owner and patent holder, Novo Nordisk, to [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":130221,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[97],"tags":[14730,18939],"dealstore":[],"offerexpiration":[],"class_list":["post-130220","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-legal","tag-compounding","tag-glp1"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Has GLP-1 Compounding Come to an End? - Som2ny Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fivemor.com\/?p=130220\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Has GLP-1 Compounding Come to an End? - Som2ny Network\" \/>\n<meta property=\"og:description\" content=\"Compounding GLP-1 medications, drugs related to immensely popular name-brand drugs such as Ozempic and Wegovy, has been going on since 2022 despite issued patents covering these name-brand drugs.\u00a0 This is because the FDA suspended enforcement of patents covering these name-brand drugs due to the inability of the drug owner and patent holder, Novo Nordisk, to [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fivemor.com\/?p=130220\" \/>\n<meta property=\"og:site_name\" content=\"Som2ny Network\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-13T07:46:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/03\/Blog-Images.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/fivemor.com\/?p=130220#article\",\"isPartOf\":{\"@id\":\"https:\/\/fivemor.com\/?p=130220\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371\"},\"headline\":\"Has GLP-1 Compounding Come to an End?\",\"datePublished\":\"2025-03-13T07:46:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/fivemor.com\/?p=130220\"},\"wordCount\":273,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/fivemor.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/?p=130220#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/03\/Blog-Images.png\",\"keywords\":[\"Compounding\",\"GLP1\"],\"articleSection\":[\"Legal\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/fivemor.com\/?p=130220#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fivemor.com\/?p=130220\",\"url\":\"https:\/\/fivemor.com\/?p=130220\",\"name\":\"Has GLP-1 Compounding Come to an End? - Som2ny Network\",\"isPartOf\":{\"@id\":\"https:\/\/fivemor.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/fivemor.com\/?p=130220#primaryimage\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/?p=130220#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/03\/Blog-Images.png\",\"datePublished\":\"2025-03-13T07:46:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/fivemor.com\/?p=130220#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fivemor.com\/?p=130220\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/?p=130220#primaryimage\",\"url\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/03\/Blog-Images.png\",\"contentUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/03\/Blog-Images.png\",\"width\":1280,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fivemor.com\/?p=130220#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/fivemor.com\/?bp_activities=1\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Has GLP-1 Compounding Come to an End?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fivemor.com\/#website\",\"url\":\"https:\/\/fivemor.com\/\",\"name\":\"Som2ny Network\",\"description\":\"Daily Deals\",\"publisher\":{\"@id\":\"https:\/\/fivemor.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fivemor.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fivemor.com\/#organization\",\"name\":\"Som2ny Network\",\"url\":\"https:\/\/fivemor.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"contentUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"width\":300,\"height\":86,\"caption\":\"Som2ny Network\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/fivemor.com\"],\"url\":\"https:\/\/fivemor.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Has GLP-1 Compounding Come to an End? - Som2ny Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fivemor.com\/?p=130220","og_locale":"en_US","og_type":"article","og_title":"Has GLP-1 Compounding Come to an End? - Som2ny Network","og_description":"Compounding GLP-1 medications, drugs related to immensely popular name-brand drugs such as Ozempic and Wegovy, has been going on since 2022 despite issued patents covering these name-brand drugs.\u00a0 This is because the FDA suspended enforcement of patents covering these name-brand drugs due to the inability of the drug owner and patent holder, Novo Nordisk, to [&hellip;]","og_url":"https:\/\/fivemor.com\/?p=130220","og_site_name":"Som2ny Network","article_published_time":"2025-03-13T07:46:03+00:00","og_image":[{"width":1280,"height":627,"url":"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/03\/Blog-Images.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fivemor.com\/?p=130220#article","isPartOf":{"@id":"https:\/\/fivemor.com\/?p=130220"},"author":{"name":"admin","@id":"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371"},"headline":"Has GLP-1 Compounding Come to an End?","datePublished":"2025-03-13T07:46:03+00:00","mainEntityOfPage":{"@id":"https:\/\/fivemor.com\/?p=130220"},"wordCount":273,"commentCount":0,"publisher":{"@id":"https:\/\/fivemor.com\/#organization"},"image":{"@id":"https:\/\/fivemor.com\/?p=130220#primaryimage"},"thumbnailUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/03\/Blog-Images.png","keywords":["Compounding","GLP1"],"articleSection":["Legal"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/fivemor.com\/?p=130220#respond"]}]},{"@type":"WebPage","@id":"https:\/\/fivemor.com\/?p=130220","url":"https:\/\/fivemor.com\/?p=130220","name":"Has GLP-1 Compounding Come to an End? - Som2ny Network","isPartOf":{"@id":"https:\/\/fivemor.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fivemor.com\/?p=130220#primaryimage"},"image":{"@id":"https:\/\/fivemor.com\/?p=130220#primaryimage"},"thumbnailUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/03\/Blog-Images.png","datePublished":"2025-03-13T07:46:03+00:00","breadcrumb":{"@id":"https:\/\/fivemor.com\/?p=130220#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fivemor.com\/?p=130220"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/?p=130220#primaryimage","url":"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/03\/Blog-Images.png","contentUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/03\/Blog-Images.png","width":1280,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/fivemor.com\/?p=130220#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fivemor.com\/?bp_activities=1"},{"@type":"ListItem","position":2,"name":"Has GLP-1 Compounding Come to an End?"}]},{"@type":"WebSite","@id":"https:\/\/fivemor.com\/#website","url":"https:\/\/fivemor.com\/","name":"Som2ny Network","description":"Daily Deals","publisher":{"@id":"https:\/\/fivemor.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fivemor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fivemor.com\/#organization","name":"Som2ny Network","url":"https:\/\/fivemor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/#\/schema\/logo\/image\/","url":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","contentUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","width":300,"height":86,"caption":"Som2ny Network"},"image":{"@id":"https:\/\/fivemor.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","caption":"admin"},"sameAs":["https:\/\/fivemor.com"],"url":"https:\/\/fivemor.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts\/130220","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=130220"}],"version-history":[{"count":0,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts\/130220\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/media\/130221"}],"wp:attachment":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=130220"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=130220"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=130220"},{"taxonomy":"dealstore","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fdealstore&post=130220"},{"taxonomy":"offerexpiration","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fofferexpiration&post=130220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}